Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)

(2015) D. Thaçi et al.   BRITISH JOURNAL OF DERMATOLOGY

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis

(2015) Philip J. Mease   CURRENT OPINION IN RHEUMATOLOGY

Secukinumab: First Global Approval

(2015) Mark Sanford et al.   DRUGS

Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer

(2015) Lavinia Nardinocchi et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis

(2015) Kristian Reich et al.   EXPERIMENTAL DERMATOLOGY

Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis

(2015) R.G. Langley et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy

(2015) Erik Letko et al.   OPHTHALMOLOGY

Interleukin 23 Levels Are Increased in Carotid Atherosclerosis

(2015) Azhar Abbas et al.   STROKE

Current Concepts in Psoriatic Arthritis: Pathogenesis and Management

(2014) K Vlam et al.   ACTA DERMATO-VENEREOLOGICA

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

(2014) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

(2014) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

(2014) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Psoriasis prevalence among adults in the United States

(2014) Tara D. Rachakonda et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial

(2014) C. Paul et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

(2014) H. Saeki et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)

(2014) C. Paul et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

(2014) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model

(2014) Andrea Chiricozzi et al.   PLoS One

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

(2014) Mark C. Genovese et al.   Arthritis & Rheumatology

Burden of Disease: Psoriasis and Psoriatic Arthritis

(2013) Wolf-Henning Boehncke et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-17 in psoriasis: Implications for therapy and cardiovascular co-morbidities

(2013) Jackelyn B. Golden et al.   CYTOKINE

Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis

(2013) Bruce W. Kirkham et al.   IMMUNOLOGY

Dermal γδ T cells — A new player in the pathogenesis of psoriasis

(2013) Yihua Cai et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Specific targeting of interleukin-23p19 as effective treatment for psoriasis

(2013) Adriane A. Levin et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study

(2013) B. Sigurgeirsson et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials

(2013) Andrew D. Dick et al.   OPHTHALMOLOGY

Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder

(2013) Jae-Won Kim et al.   Psychiatry Investigation

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

(2013) David A Martin et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study

(2012) P. Rich et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Chronic Skin-Specific Inflammation Promotes Vascular Inflammation and Thrombosis

(2012) Yunmei Wang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings

(2012) David A. Martin et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-17 Mediated Inflammation Promotes Tumor Growth and Progression in the Skin

(2012) Donggou He et al.   PLoS One

Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review

(2011) Sue Langham et al.   BMC Medical Research Methodology

The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis

(2011) Yang LIU et al.   International Journal of Rheumatic Diseases

Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab

(2011) Hideshi TORII et al.   JOURNAL OF DERMATOLOGY

IL-17 receptor and its functional significance in psoriatic arthritis

(2011) Siba P. Raychaudhuri et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Signaling of interleukin-17 family cytokines in immunity and inflammation

(2010) Seon Hee Chang et al.   CELLULAR SIGNALLING

Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis

(2009) Erin G. Harper et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis

(2009) Antonella Di Cesare et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides

(2008) Camilla Jandus et al.   ARTHRITIS AND RHEUMATISM

Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis

(2008) Dennis A. Revicki et al.   DERMATOLOGY

Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis

(2008) Chizuko Koga et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY